What is Maat?
Headquartered in Lyon, France, and established in 2014, MaaT Pharma is a pioneer in the development of microbiome-based biotherapeutics. The company focuses on restoring the gut ecosystem to improve clinical outcomes for patients suffering from severe diseases, particularly in the oncology space. By utilizing advanced microbiome restoration therapy, the firm addresses critical unmet medical needs, positioning itself as a key player in the global biotechnology sector. Its market position is defined by a rigorous scientific approach to drug discovery and a scalable manufacturing process that supports its clinical-stage ambitions.
How much funding has Maat raised?
Maat has raised a total of $100.7M across 6 funding rounds:
Unspecified
$1.3M
Unspecified
$1.1M
Series A
$11.2M
Series B
$29.5M
Share Placement
$14M
Debt
$43.7M
Unspecified (2015): $1.3M with participation from Seventure Partners
Unspecified (2015): $1.1M led by Seventure Partners
Series A (2016): $11.2M supported by Seventure Partners
Series B (2020): $29.5M featuring Biocodex, SymBiosis, Seventure Partners, Bpifrance, and Crédit Mutuel Innovation
Share Placement (2025): $14M backed by RiPSIM Technologies, Biocodex, and Bpifrance Investissement
Debt (2025): $43.7M with participation from European Investment Bank
Key Investors in Maat
Seventure Partners
Seventure Partners is an active partner of innovative companies in the fields of digital technologies and life sciences, focusing on health, nutrition, and sustainable biotechnologies.
Biocodex
Biocodex is a multinational pharmaceutical company specializing in microbiota and neurology products with a global commitment to healthcare innovation.
European Investment Bank
The European Investment Bank is the European Union's nonprofit long-term lending institution, providing strategic financing to support major innovation and infrastructure projects.
What's next for Maat?
With the recent infusion of capital, MaaT Pharma is well-positioned to scale its clinical trials and expand its therapeutic reach. The strategic allocation of these funds will likely prioritize the advancement of its lead candidates through late-stage clinical development, while simultaneously enhancing its proprietary technology platform. As the company transitions into a more mature phase of its lifecycle, the focus will shift toward commercial readiness and potential international partnerships. The continued support from institutional investors suggests a clear path toward long-term value creation and the potential for significant breakthroughs in microbiome-based medicine.
See full Maat company page
